Method of treating glaucoma and ischemic retinopathy
CA 2272665 C · Owner: Pfizer Products Inc. · Inventors: Howard, Harry Ralph
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed is a pharmaceutical composition for treating glaucoma and ischemic retinopathy in a mammal comprising a, pharmaceutically acceptable diluent and a therapeutically effective amount of a compound of the formula: (see above formula), (wherein Ar is an aryl such as benzoisothiazolyl; n is 1 or 2; and X and Y together with the benzene ring to which they are attached, form a fused cyclic ring system such as optionally substituted oxindole) or a pharmaceutically acceptable acid addition salt thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 21, 1999 and granted August 5, 2003. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 21, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 21, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.